BC Extra | Sep 26, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

Neurogene Inc . hired Christine Mikail as president. She is a co-founder of neurology specialty pharma Neumentum Inc. and biotech consulting firm Ferndale Advisors. Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in...
BC Innovations | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
BC Extra | Jan 13, 2016
Politics & Policy

Coalition aims for cancer MoonShot

Stakeholders including biopharma companies, academic research centers, community oncologists, payer Independence Blue Cross (Philadelphia, Pa.) and Bank of America Corp. (NYSE:BAC) launched the MoonShot 2020 initiative to test combination therapies in immuno-oncology. The initiative said...
BC Week In Review | Oct 26, 2015
Financial News

Precision Biologics completes venture financing

Precision Biologics Inc. , Dallas, Texas   Business: Cancer, Diagnostic   Date completed: 2015-10-19   Type: Venture financing   Raised: $50 million   Investor: NantWorks  ...
BC Extra | Oct 20, 2015
Financial News

NantWorks invests $50M in Precision Biologics

NantWorks LLC (Los Angeles, Calif.) invested $50 million in Precision Biologics Inc. (Dallas, Texas), giving it a majority stake in the company. Precision Biologics is developing a pipeline of mAbs and companion diagnostics to treat...
BC Week In Review | Jun 8, 2015
Clinical News

Ensituximab: Completed Phase II enrollment

Precision completed enrollment of 47 patients in an open-label, U.S. Phase II trial evaluating 3 mg/kg IV NPC-1C once every 2 weeks. Precision Biologics Inc. , Dallas, Texas   Product: Ensituximab ( NEO-101 , NPC-1C )   Business: Cancer...
BC Week In Review | Apr 28, 2014
Clinical News

NEO-102: Interim Phase I/IIa data

Interim data from 9 evaluable patients with refractory metastatic pancreatic and colorectal cancer in an open-label, U.S. Phase I/IIa trial showed that IV NEO-102 led to 5 cases of stable disease. Of the 16 patients...
BC Week In Review | Jun 10, 2013
Clinical News

Ensituximab: Phase I/IIa data

Preliminary data from 17 evaluable patients with advanced pancreatic and colorectal cancer who progressed on standard therapy in the Phase IIa portion of an open-label, U.S. Phase I/IIa trial showed that 1.5 mg/kg IV ensituximab...
BC Week In Review | Apr 22, 2013
Clinical News

Ensituximab: Phase I data

An open-label, dose-escalation Phase I trial in 15 patients with advanced pancreatic and colorectal cancer who progressed on standard therapy showed that 1.5 mg/kg IV ensituximab every 2 weeks for 8 weeks was well tolerated...
BC Week In Review | Nov 8, 2010
Clinical News

NPC-1C regulatory update

FDA granted Orphan Drug designation for Neogenix's ensituximab to treat pancreatic cancer. The chimeric mAb derived from immunogenic glycoprotein is in Phase I testing to treat advanced pancreatic and colorectal cancer. Neogenix Oncology Inc. , Great...
Items per page:
1 - 10 of 10